ÂÜẠ̀ẨÂ×

Edward C. Saltzman has served as a member of the board of directors since September 2022. Mr. Saltzman has nearly four decades of consulting and strategic development experience in the pharmaceutical, specialty pharmaceutical and biotechnology industries. He currently serves as Head of Biotech Strategy at Lumanity Inc., an Arsenal Capital Partners company focused on improving patient health by accelerating and optimizing access to medical advances. In 1993, Mr. Saltzman founded Defined Health Inc., an asset development strategy consulting firm, and led it to becoming a preeminent advisor to senior management and boards of directors of biotechnology and biopharmaceutical companies, including those developing novel drug discovery platforms. Following the sale of Defined Health to Cello Health plc in January 2017, Mr. Saltzman served as President of Cello Health’s bio-consulting business unit until mid-2017, when he became the unit’s Executive Chairman, a position he held until March of 2022 when Cello Health was merged with several other businesses and renamed Lumanity.

Mr. Saltzman is a frequent speaker on industry issues and is a past recipient of the LES Frank Barnes Mentoring Award for his contributions to education in the life sciences sector. Mr. Saltzman currently is a Venture Advisor to the Israel Biotech Fund and Hibiscus Capital Management and a member of the Licensing Executives Society and the New York Pharma Forum. He previously served on the boards of directors of Vidac Pharmaceuticals Inc. and Saniona AB.

Mr. Saltzman holds a bachelor’s degree in Journalism from New York University.